• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Fresenius Medical Invests Additional $25M in Biotech Platform Humacyte

by Jasmine Pennic 08/30/2021 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Fresenius Medical Invests Additional $25M in Biotech Platform Humacyte

What You Should Know:

 Fresenius Medical Care (FMC) today announced its plans to invest an additional $25 million in clinical-stage biotechnology platform company Humacyte following the extension of its collaboration in June. Fresenius Medical Care acquired a stake in Humacyte in 2018 for $150M as part of a strategic partnership.

Following the merger of Humacyte with a special purpose acquisition company (SPAC), FMC is increasing its position in the newly combined entity as the lead investor of a private investment in public equity (PIPE). The combined company, called Humacyte, is listed and trades on the Nasdaq exchange under HUMA.

Regenerative Innovations Harnessing the Body’s Own Ability to Heal

Humacyte is developing implantable human acellular vessels for multiple vascular repair, reconstruction and replacement. These vessels are biologically produced blood vessels made from banked human smooth muscle cells; they are manufactured to be non- immunogenic and are to be available “off the shelf” when needed by a patient. Among numerous applications, the product is now being investigated in a clinical study for use as a vascular access for hemodialysis patients and may prove more effective than conventional synthetic grafts and fistulas in reducing infection as well as central venous catheter use. Other possible applications include reconstruction and repair from traumatic injury, and for implants for various vascular diseases.

Humacyte and Fresenius Medical Care had already expanded their collaboration in June: In addition to the vascular access and peripheral arterial disease applications, Fresenius Medical Care was granted exclusive rights to market the human acellular vessel outside the United States, including enhancements and modifications for vascular trauma applications.

“Our partnership with Fresenius Medical Care has developed very positively over the last three years, and we are very pleased with the company’s renewed commitment to our shared goals,” said Laura Niklason, MD, PhD, the Chief Executive Officer of Humacyte. “Our two teams have worked well to prepare for the commercialization of our human acellular vessels globally since the formation of the partnership, and we look forward to collaborating further to benefit patients and care providers, as well as the growth of our two companies.”

The biotechnology-derived blood vessel is an investigational product and is currently subject to late-stage clinical trials in the United States and Europe. Humacyte plans to file for regulatory approval in both markets after their completion Fresenius Medical Care will support the approval processes and plans the introduction in other markets worldwide with Humacyte.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Biotech, Biotech startups

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |